Edmund Tsui, MD: Making the Most of the ARVO 2021 Agenda
The UCLA expert discusses the lengthy virtual agenda of this year's meeting, as well as his own session recommendations and key discussions.
Statins May Not Halt Progression from AMD to nAMD
These findings corroborate similar conclusions presented last year at ARVO.
Study Suggests Glaucoma-Induced Vision Loss is on the Rise
Age-adjusted glaucoma blindness has nonetheless seen a downward trend between 2000 and 2020.
ADVM-022 Gene Therapy for nAMD May Reduce Anti-VEGF Injection Burden
The single-injection investigative gene therapy may help with providing continuous expression of aflibercept.
Gene Therapy BIIB112 Promising for X-Linked Retinitis Pigmentosa
The AAV8 vector–based gene therapy was associated with improvements in 2 measures of visual function.
Home Monitoring May Reduce Neovascularization Risks in Patients with AMD
An FDA-approved device, provided to eligible patients with age-related macular degeneration, showed ability to detect CNV risks over 5 years.
Delaying Anti-VEGF Treatment for DME Likely to Worsen Visual Outcomes
The majority of patients with a treatment gap longer than 12 weeks had worsening visual acuity, notes a new ARVO study.
Dapagliflozin May Benefit Patients with Diabetic Retinopathy
The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.
Childhood Strabismus Increases Risk for Mental Health Disorders
More research is needed to fully understand the associations with different types of strabismus
Undetected Eye Disease Burden High in African American Populations
Patients with diabetes mellitus have the highest odds of being diagnosed with an undetected eye disease.
Faricimab and PDS Ranibizumab May Progress Anti-VEGF Treatment Duration
An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.
Cardiovascular Disease Risk Factors More Prevalent in Visually-Impaired Adults
A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.
Aflibercept Benefits Non-Proliferative Diabetic Retinopathy Visual Acuity at 2 Years
Allen Ho, MD, discusses the Protocol W outcomes and what they indicate for prescribing ophthalmologists.
Interim Data Shows Real-World Insights into Ranibizumab Treatment Practices
The PACIFIC study is currently evaluating health care management practice with intravitreal ranibizumab 0.5 mg for various ophthalmologic diseases.
Study Explores Associations Between DME and Proliferative Diabetic Retinopathy
An ARVO 2021 study characterizes patients with diabetic retinopathy who have also developed diabetic macular edema.
Study Identifies Potential Type 2 Diabetes plus Dry Eye Biomarkers
New research shows patients with both conditions have greater levels of particular cytokines and metabolic proteins.
Expanding Sepofarsen Understanding in LCA10
After promising early findings for the investigative therapy in a rare form of blindness, investigators turn to the next phase.
Glycemic Control Not Always Enough to Prevent Vision Loss in Diabetics
New research from ARVO 2020 suggests patients with diabetic eye disease can still experiences losses in visual acuity, even with glycemic control.
Impact of Hereditary Retinitis Pigmentosa on Activity, Quality of Life
A survey of 19 patients with hereditary retinitis pigmentosa details the impact of the disease on the quality of life and daily activity of patients and caregivers.
Patient Anxiety Linked to Pain from Anti-VEGF Injections
Gauging patient wellbeing prior to intravitreal injections may help inform clinicians as to who may fare worse with the treatment.
Sepofarsen Benefits Genetic Form of Blindness in Early Trials
A breakdown of a new 12-month, phase 1b/2 assessment of the RNA therapy in patients with LCA10.
Few RVO Patients Prescribed Anti-VEGF after Macular Edema Diagnosis
A new assessment shows about 60% of treatment-naive patients are not prescribed the most common drug class within 1 year of secondary edema.
Visual Impairment, Dementia Are Detrimental to Independence of Older Adults
New research suggests the presence of either condition can wreak havoc on an older adult's ability for movement, self-care, and household activities.
New AI Model Could Aid in Diagnosis of Age-Related Macular Degeneration
A new AI model from the New York Eye and Ear Infirmary of Mount Sinai boasts 99.2% accuracy for diagnosing intermediate or late AMD.
Vitamin D and Homotaurine Show Potential Benefit for Macular Degeneration
Discussing the results of a study examining impact of vitamin D and homotaurine supplementation on early to intermediate age-related macular degeneration.
Fluoroquinolone Effective Initial Treatment for MRSA Keratitis
Fortified vancomycin causes antibiotic resistance and corneal toxicity.
Brolucizumab Linked to Decreases in nAMD Disease Activity Versus Aflibercept
Rishi Singh, MD, discusses differences in disease activity noted among nAMD patients enrolled in the pivotal HAWK and HARRIER trials.
Sumit Sharma, MD: Learning About NIU-PS Disease Course from Fellow Eyes
Discussing what data from fellow eyes of a 3-year study tell us about disease course of non-infectious uveitis of the posterior segment with an assistant professor from the Cole Eye Institute.
Superior Placement Risk Factor For Premature Monocanalicular Stent Extrusion
Male sex and younger age are also risk factors for premature stent extrusion.
Pooled Analysis Highlights Safety, Efficacy of Satralizumab for NMOSD
A Q&A with the medical director of clinical ophthalmology with Genentech about the humanized monoclonal antibody in treatment of NMOSD.